Hologic announced that the Company’s Selenia Dimensions three-dimensional (3-D) digital mammography tomosynthesis system has been scheduled to be reviewed by the Radiological Devices Panel (Panel) of the U.S. Food and Drug Administration (FDA) on September 24, 2010 as part of the Company’s pre-market approval (“PMA”) application.

Hologic announced that Glenn Muir, Chief Financial Officer, will present at the Canaccord Genuity 30th Annual Growth Conference 2010 on Wednesday, August 11, 2010 at 1:00 p.m. (Eastern).

Hologic announced plans to release its third quarter fiscal 2010 operating results on Monday, August 2, 2010 after market close.

Hologic announced that final data analysis from the first large-scale independent evaluation of clinical performance of Cervista® HPV HR compared to Hybrid Capture 2 (hc2), were presented in Montreal Canada at the 26th International Papillomavirus Conference.

Hologic announced today that it has entered into a definitive agreement to acquire Sentinelle Medical Inc. (Sentinelle Medical), a leading provider of Magnetic Resonance Imaging (MRI) breast coils, tables and visualization software.

Hologic To Present At The 2010 Wells Fargo Securities Healthcare Conference in Boston on June 23rd, 2010 at 11:15 a.m.

Hologic announced today that the Hologic Selenia® digital mammography system with a tungsten tube has received “Mammographic Type Test” certification by the European Reference Organization (EUREF) Council for Quality Assured Breast Screening and Diagnostic Services.

Hologic To Present At The 9th Annual Needham Healthcare Conference in New York City on June 9th, 2010 at 9:20 a.m.

Hologic To Present At Jefferies 2010 Global Life Sciences Conference in New York City on June 8th, 2010 at 8:00 a.m. Interested parties are invited to listen to the live audio webcasts of Hologic's investor presentations on the investor section of the company's website at www.hologic.com/investor. An archive of the presentations will be available for replay following each conference.

Hologic celebrates a new era of birth control options for women today with the availability of its Adiana® permanent contraception system.

Hologic today announced that interim data from the first large-scale independent evaluation of clinical performance of Cervista® HPV HR compared to Hybrid Capture 2 (hc2), were presented at the 4th Biennial Meeting of AOGIN (Asia-Oceanic Research Organization in Genital Infection and Neoplasia) in New Delhi, India on March 26-28, 2010.

Hologic today announced it has entered into a settlement agreement with Ethicon Endo-Surgery, Inc. (EES), a Johnson & Johnson company.

Hologic today announced the expansion of its Promise to Me global women’s health initiative to raise awareness and provide donations for women who lack access to cervical cancer screening.